Author Search Results :: UTM Library Massive Scholar Tracking

1

$Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data$

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data by Fateeha Furqan, Mehdi Hamadani

Published 2022-03-01

Get full text

Article

2

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL by Madiha Iqbal, Bipin N Savani, Mehdi Hamadani

Published 2022-01-01

Get full text

Article

3

The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time by Ruah AlYamany, Mohamed A. Kharfan-Dabaja, Mehdi Hamadani, Alfadel Alshaibani, Mahmoud Aljurf

Published 2022-05-01

Get full text

Article

4

Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas by Ibrahim N. Muhsen, Riad El Fakih, Mehdi Hamadani, Hillard M. Lazarus, Mohamed A. Kharfan-Dabaja, Mahmoud Aljurf

Published 2022-06-01

Get full text

Article

5

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline... by Anita D'Souza, Kathryn Flynn, Saurabh Chhabra, Binod Dhakal, Mehdi Hamadani, Kirsten Jacobsen, Marcelo Pasquini, Dorothee Weihrauch, Parameswaran Hari

Published 2017-12-01

Get full text

Article

6

CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. by Kechang Liu, Bryan A Anthony, Martha M Yearsly, Mehdi Hamadani, Alice Gaughan, Jiao-Jing Wang, Steven M Devine, Gregg A Hadley

Published 2011-01-01

Get full text

Article

7

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA by Nirav N Shah, Timothy Fenske, Bryon Johnson, Aniko Szabo, Sumana Devata, Walter Longo, Tyce Kearl, Anthony Zamora, Parameswaran Hari, Dina Schneider, Mehdi Hamadani

Published 2023-08-01

Get full text

Article

8

$In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine$

In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine by Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo‐Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Danilo Cucchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni

Published 2024-02-01

Get full text

Article

9

$Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)$